CA IX directly participates in these hallmarks, as supported by the fact that its suppression, mutation/deletion, pharmacologic inhibition, or treatment with monoclonal antibodies result in significantly reduced growth of tumor xenografts in vivo [48, 61–64]. The gene discussed is CA9; the disease is neoplasm.